OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources
Link to OncoLink

Prognostic Value of Initial Magnetic Resonance Imaging Growth Rates for World Health Organization Grade II Glioma

Reviewer: Eric Shinohara MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de diciembre del 2006

Author: Pallud J. et al
Source: Ann Neurol
2006;60:380-383

Objective

To determine if MRI-based measurement of growth rate prior to treatment has prognostic value in grade II gliomas.

Methods

  • 143 consecutive patients diagnosed between 1992-2004
  • Older than 17 years of age
  • Absence of contrast enhancement
  • Astrocytoma, oligodendroglioma, or mixed glioma
  • At least 2 MRI studies pre-treatment, at least 3 months apart

Results

  • Patient characteristics
    • Median age 34
    • Symptoms at dx: 7 patients asymptomatic, 124 patients with seizures, 12 patients with headache, 7 patients with neurologic deficits
    • Median tumor volume 74.5 cm 3: 54 patients had histologic diagnosis via biopsy, 34 patients had partial resections, 40 had subtotal resections, and 15 had total resections
    • 92 oligodendrogliomas, 24 astrocytomas, 27 mixed histology
    • Median Ki-97 proliferation index 5% (72% of cases were assessable)
  • Radiology
    • Median of 3 tumor measurements prior to treatment
    • Median duration of repeat measurements was 21.7 months
    • Median Individual Radiological Growth Rate (IGR) 4.4 mm/year
    • Two Groups: 121 <8mm/year à low risk (LR) and 22 >8mm/year à high risk (HR)
    • No significant difference between the 2 groups regarding various demographics and treatment factors except that more biopsies done in LR group
  • Survival
    • Median clinical follow-up after radiologic diagnosis was 6.5 years
    • 18.1% of LR patients died during this time versus 45.5% in HR group; median time to death was 6.7 years in LR group and 4.9 years in HR group
    • Median survival was 5.16 years in HR group versus 15 years in LR group
    • Univariate Analysis: inverse correlation between IGR and survival (p<0.001); histology, tumor volume, age, neurologic deficits, and Ki-67 proliferation score not significant predictors of survival
    • Multivariate Analysis: IGR (p<0.0001) and tumor volume (p=0.034) were independent prognostic factors for survival

Discussion

  • IGR measurements prior to treatment in supratentorial grade II gliomas are predictive of prognosis
    • Previous studies have shown age >40, astrocytoma histology, tumor diameter >6 cm, neurologic defects, and lesions crossing midline have worse prognosis.
    • Lack of significance for several other prognostic factors may be due to small sample size.
  • Limitations of histologic diagnosis
    • Limited because it is "static"
    • Limited to part of the tumor, particularly in biopsies or partial resections
    • Conversely, tumor growth rate a macroscopic, dynamic parameter
    • In tumors growing >8 mm/year, worse prognosis despite absence of anaplastic transformation à seem to behave more like anaplastic gliomas with median survival of 5.16 years
  • Study may be limited as 2 MRIs may not accurately determine growth velocity

OncoLink I wish u knew...

Ms. Gambino talks about the complexity of cancer care and the need for patients and families to have help in navigating from diagnosis and treatment decisions to survivorship. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS